The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.

被引：0

作者：

Tougeron, David

Dahan, Laetitia

El Hajbi, Farid

Le Malicot, Karine

Evesque, Ludovic

Aparicio, Thomas

Bouche, Olivier

Bonichon-Lamichhane, Nathalie

Chibaudel, Benoist

Angelergues, Antoine

Bordere, Anais

Phelip, Jean-Marc

Mabro, May

Artru, Pascal

Louvet, Christophe

机构：

[1] Univ Poitiers Hosp, Gastroenterol Dept, Poitiers, France

[2] Univ Hosp Timone, Hepatogastroenterol & Oncol Dept, Marseille, France

[3] Ctr Oscar Lambret, Lille, France

[4] FFCD, Dijon, France

[5] INSERM, U1231, Dijon, France

[6] Ctr Antoine Lacassagne, Nice, France

[7] Hop St Louis, AP HP, Dept Gastroenterol, Paris, France

[8] Hop Robert Debr, Reims, France

[9] Clin Tivolis Ducos, Bordeaux, France

[10] Hosp Franco Britann, Fdn Cognacq Jay, Med Oncol, Levallois Perret, France

[11] Diaconesses Croix Simon Hosp, Paris, France

[12] St Malo Hosp, St Malo, France

[13] Univ Jean Monnet, St Etiennes, France

[14] Hop Foch, Suresnes, France

[15] Hop Prive Jean Mermoz, Lyon, France

[16] Inst Mutualiste Montsouris, Dept Med Oncol, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4036

引用

页数：1

共 50 条

[31] FOLFiRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab for Patients with Advanced or Metastatic Adenocarcinoma of The Stomach or Gastroesophageal Junction As Second-Line Therapy - Interim Safety and Efficacy Results from The Phase II Ramiris Study (AIO-STO-0415) of the German Gastric Group at AIO
Lorenzen, Sylvie
Thuss-Patience, Peter
Pauligk, Claudia
Goekkurt, Eray
Ettrich, Thomas J.
Lordick, Florian
Stahl, Michael
Reichardt, Peter
Soekler, Martin
Pink, Daniel
Probst, Stephan
Alguel, Nana
Hinke, Axel
Goetze, Thorsten
Al-Batran, Salah-Eddin
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 58 - 58
[32] A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
Liu, Yuguo
Luan, Lijuan
Wang, Xingli
ONCOTARGETS AND THERAPY, 2015, 8 : 1061 - 1068
[33] Phase II study of irinotecan plus leucovorin and bolus 5 fluorouracil as first or second line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma
Gerolymos, M.
Koutras, A.
Kontogeorgou, E.
Iconomou, G.
Vourli, G.
Tsiata, E.
Makatsoris, T.
Chrysanthopoulos, C.
Kalofonos, H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[34] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
Cao, Ranhua
Zhang, Shuai
Ma, Dedong
Hu, Likuan
MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
[35] The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).
Cervantes-Ruiperez, Andres
Markman, Ben
Siena, Salvatore
Pericay, Carles
Aprile, Giuseppe
Bridgewater, John A.
Cubillo, Antonio
Waterston, Ashita Marie
Garcia-Carbonero, Rocio
Kozloff, Mark
McKendrick, Joseph James
Samuel, Leslie M.
Perez-Fidalgo, Jose Alejandro
Strickland, Andrew H.
Bencardino, Katia
Moya, Irene
Lutrino, Stefania Eufemia
Mancao, Christoph
Manenti, Luigi
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[36] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Taroh Satoh
Kyung Hee Lee
Sun Young Rha
Yasutsuna Sasaki
Se Hoon Park
Yoshito Komatsu
Hirofumi Yasui
Tae-You Kim
Kensei Yamaguchi
Nozomu Fuse
Yasuhide Yamada
Takashi Ura
Si-Young Kim
Masaki Munakata
Soh Saitoh
Kazuto Nishio
Satoshi Morita
Eriko Yamamoto
Qingwei Zhang
Jung-mi Kim
Yeul Hong Kim
Yuh Sakata
Gastric Cancer, 2015, 18 : 824 - 832
[37] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Satoh, Taroh
Lee, Kyung Hee
Rha, Sun Young
Sasaki, Yasutsuna
Park, Se Hoon
Komatsu, Yoshito
Yasui, Hirofumi
Kim, Tae-You
Yamaguchi, Kensei
Fuse, Nozomu
Yamada, Yasuhide
Ura, Takashi
Kim, Si-Young
Munakata, Masaki
Saitoh, Soh
Nishio, Kazuto
Morita, Satoshi
Yamamoto, Eriko
Zhang, Qingwei
Kim, Jung-mi
Kim, Yeul Hong
Sakata, Yuh
GASTRIC CANCER, 2015, 18 (04) : 824 - 832
[38] NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Thibault, C.
Elaidi, R. T.
Pouessel, D.
Flechon, A.
Borchiellini, D.
Barthelemy, P.
Huillard, O.
Rouabah, M.
Braychenko, E.
Helali, I.
Audenet, F.
Oudard, S.
ANNALS OF ONCOLOGY, 2020, 31 : S723 - S723
[39] Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial
Cheng, Xiangdong
Xu, Zhiyuan
Hu, Can
Zhang, Yanqiang
Pengfei, Yu
Du, Yian
Yang, Litao
Zhang, Ruolan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40] Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma
Kunisaki, C
Imada, T
Yamada, R
Hatori, S
Ono, H
Otsuka, Y
Matsuda, G
Nomura, M
Akiyama, H
Kubo, A
Shimada, H
ANTICANCER RESEARCH, 2005, 25 (04) : 2973 - 2977

← 1 2 3 4 5 →